In the November edition of the Hardman Monthly Newsletter, Nigel Hawkins assesses the achievements of AIM – and how it has thrived, despite a challenging financial environment, in recent years.

01 Nov 2017
AIM – A Decade of Achievement
Sinclair Pharma (SPH:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 22.0 | Scancell Holdings Plc (SCLP:LON), 12.0 | Allergy Therapeutics plc (AGY:LON), 19.0 | City of London Investment Group PLC (CLIG:LON), 407 | Tissue Regenix Group plc (TRX:LON), 0 | Avacta Group PLC (AVCT:LON), 116 | Alliance Pharma plc (APH:LON), 94.0 | Chamberlin plc (CMH:LON), 5.0 | Morses Club Plc (MCL:LON), 5.0 | Murgitroyd Group (MUR:LON), 0 | ValiRx PLC (VAL:LON), 12.0
-
-
-
Nigel Hawkins
-
42 pages
-


Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
AIM – A Decade of Achievement
Sinclair Pharma (SPH:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 22.0 | Scancell Holdings Plc (SCLP:LON), 12.0 | Allergy Therapeutics plc (AGY:LON), 19.0 | City of London Investment Group PLC (CLIG:LON), 407 | Tissue Regenix Group plc (TRX:LON), 0 | Avacta Group PLC (AVCT:LON), 116 | Alliance Pharma plc (APH:LON), 94.0 | Chamberlin plc (CMH:LON), 5.0 | Morses Club Plc (MCL:LON), 5.0 | Murgitroyd Group (MUR:LON), 0 | ValiRx PLC (VAL:LON), 12.0
- Published:
01 Nov 2017 -
Author:
Nigel Hawkins -
Pages:
42 -
In the November edition of the Hardman Monthly Newsletter, Nigel Hawkins assesses the achievements of AIM – and how it has thrived, despite a challenging financial environment, in recent years.